IDH1 and astrocytoma (excluding glioblastoma): Notably, this reduction in GSH upon CB839 [44] is involved in the foundation for a clinical trial testing CB839 when combined with radiotherapy/temozolomide in IDH mutant grade II/III astrocytoma (NCT03528642).